Similar articles

• Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.

  [No authors listed] [No authors listed] Lancet. 1992 Jan 4;339(8784):1-15. Lancet. 1992. PMID: 1345950 Review.
• Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.

  [No authors listed] [No authors listed] Lancet. 1992 Jan 11;339(8785):71-85. Lancet. 1992. PMID: 1345869 No abstract available.
• Adjuvant therapy for all patients with breast cancer?

  Lippman ME, Hayes DF. Lippman ME, et al. J Natl Cancer Inst. 2001 Jan 17;93(2):80-2. doi: 10.1093/jnci/93.2.80. J Natl Cancer Inst. 2001. PMID: 11208870 No abstract available.
• Prevention of breast cancer recurrence with adjuvant cytotoxic or endocrine therapy.

  Rutqvist LE. Rutqvist LE. Med Oncol Tumor Pharmacother. 1991;8(3):163-8. doi: 10.1007/BF02987175. Med Oncol Tumor Pharmacother. 1991. PMID: 1803176 Review.
• Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial.

  Adjuvant Breast Cancer Trials Collaborative Group. Adjuvant Breast Cancer Trials Collaborative Group. J Natl Cancer Inst. 2007 Apr 4;99(7):516-25. doi: 10.1093/jnci/djk109. J Natl Cancer Inst. 2007. PMID: 17405996 Clinical Trial.